Cardiotoxicity of the HER2 dimerisation inhibitor pertuzumab in patients with breast cancer HER2+: A systematic review

被引：0
|
作者：
Olivares Hernandez, A. [1 ]
Escala Cornejo, R. A. [2 ]
Toribio Garcia, I. [3 ]
Figuero Perez, L. [4 ]
Vidal Tocino, R. [5 ]
Miramontes Gonzalez, J. P. [6 ]
Martin Garcia, G. [4 ]
Seijas Tamayo, R. [4 ]
Cruz-Hernandez, J. J. [7 ]
Rodriguez Sanchez, C. A. [8 ]
机构：
[1] IBSAL Inst Invest Biomed Salamanca, Dept Med Oncol, Salamanca, Spain
[2] Complejo Asistencial Avila Hosp Nuestra Senora So, Dept Med Oncol, Avila, Spain
[3] Univ Hosp Leon, Cardiol, Leon, Spain
[4] Univ Hosp Salamanca, Med Oncol, Salamanca, Spain
[5] IBSAL Inst Invest Biomed Salamanca, Dept Med Oncol, Salamanca, Spain
[6] Univ Hosp Rio Hortega, Internal Med, Valladolid, Spain
[7] Hosp Clin Univ Salamanca, Med Oncol, Salamanca, Spain
[8] IBSAL Inst Invest Biomed Salamanca, Med Oncol, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1832P
引用
收藏
页码：S1240 / S1240
页数：1
相关论文
共 50 条
  • [41] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [42] Treatment of brain metastases in patients with HER2+ breast cancer
    Bravo Marques J.M.
    [J]. Advances in Therapy, 2009, 26 (Suppl 1) : S18 - S26
  • [43] Systematic Review: Targeting HER2 in Bladder Cancer
    Koshkin, Vadim S.
    O'Donnell, Peter
    Yu, Evan Y.
    Grivas, Petros
    [J]. BLADDER CANCER, 2019, 5 (01) : 1 - 12
  • [44] Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis
    Sotiropoulou, Ioanna Myrto
    Manetas-Stavrakakis, Nikolaos
    Kourek, Christos
    Xanthopoulos, Andrew
    Magouliotis, Dimitrios
    Giamouzis, Grigorios
    Skoularigis, John
    Briasoulis, Alexandros
    [J]. CANCERS, 2024, 16 (13)
  • [45] Adjuvant therapy of HER2+ breast cancer
    Winer, E. P.
    [J]. BREAST CANCER RESEARCH, 2009, 11 : S6 - S6
  • [46] HER2/neu in systemic therapy for women with breast cancer: a systematic review
    Bindi Dhesy-Thind
    Kathleen I. Pritchard
    Hans Messersmith
    Frances O’Malley
    Leela Elavathil
    Maureen Trudeau
    [J]. Breast Cancer Research and Treatment, 2008, 109 : 209 - 229
  • [47] HER2/neu in systemic therapy for women with breast cancer:: a systematic review
    Dhesy-Thind, Bindi
    Pritchard, Kathleen I.
    Messersmith, Hans
    O'Malley, Frances
    Elavathil, Leela
    Trudeau, Maureen
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 209 - 229
  • [48] HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
    Blancas, Isabel
    Linares-Rodriguez, Marina
    Martin-Bravo, Celia
    Gomez-Pena, Celia
    Rodriguez-Serrano, Fernando
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10): : 2531 - 2540
  • [49] Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
    Shao, Nan
    Shi, Yawei
    Yu, Liang
    Ye, Runyi
    Shan, Zhen
    Zhang, Zhanqiang
    Zhang, Yunjian
    Lin, Ying
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (05): : 962 - 972
  • [50] Cardiotoxicity in HER2-positive breast cancer patients
    Gonciar, Diana
    Mocan, Lucian
    Zlibut, Alexandru
    Mocan, Teodora
    Agoston-Coldea, Lucia
    [J]. HEART FAILURE REVIEWS, 2021, 26 (04) : 919 - 935
12345